Line 7: |
Line 7: |
| !Notes | | !Notes |
| |- | | |- |
− | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR) | + | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans, Fabiola Quintero-Rivera |
| + | |Fabiola Quintero-Rivera (FQR) |
| | | | | |
| | | | | |
Line 84: |
Line 85: |
| | | | | |
| |- | | |- |
− | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''|| ||FQR | + | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff |
| + | |FQR |
| | | | | |
| | | | | |
Line 107: |
Line 109: |
| | | | | |
| |- | | |- |
− | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Sarah Rapisardo | + | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Daynna J.Wolff |
| |FQR | | |FQR |
| |PENDING | | |PENDING |